Mesoblast (NASDAQ:MESO) Stock Price Down 3.7% – Should You Sell?

Shares of Mesoblast Limited (NASDAQ:MESO) were down 3.7% during mid-day trading on Friday . The company traded as low as $7.09 and last traded at $8.07. Approximately 91,393 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 790,984 shares. The stock had previously closed at $8.38.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on MESO shares. StockNews.com downgraded Mesoblast from a “hold” rating to a “sell” rating in a research report on Wednesday, September 4th. Piper Sandler upgraded Mesoblast from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $4.00 to $11.00 in a research report on Tuesday, July 23rd. Jefferies Financial Group upgraded Mesoblast from a “hold” rating to a “buy” rating in a research report on Thursday, August 29th. Maxim Group upgraded Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research report on Tuesday, September 24th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Mesoblast in a research report on Thursday, August 29th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Mesoblast has a consensus rating of “Moderate Buy” and a consensus price target of $11.50.

Mesoblast Trading Down 1.9 %

The stock has a 50-day simple moving average of $7.88 and a two-hundred day simple moving average of $7.29. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Signaturefd LLC grew its stake in shares of Mesoblast by 128.7% during the third quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock valued at $45,000 after buying an additional 3,099 shares during the last quarter. Creative Planning bought a new position in shares of Mesoblast during the third quarter valued at about $147,000. Perkins Coie Trust Co grew its stake in shares of Mesoblast by 15.0% in the third quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock worth $94,000 after purchasing an additional 1,500 shares during the last quarter. Lazari Capital Management Inc. grew its stake in shares of Mesoblast by 6.6% in the second quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company’s stock worth $364,000 after purchasing an additional 3,300 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Mesoblast in the second quarter worth about $562,000. 1.43% of the stock is owned by institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.